TC
BNTC icon

Truvestments Capital’s Benitec Biopharma BNTC Stock Holding History

Truvestments Capital’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.8K Hold
3,834
– – 0.01% 527
2025
Q4 		$51.6K Buy
3,834
+2,339
+156% +$32.3K 0.01% 445
2025
Q3 		$21K Buy
1,495
+321
+27% +$4.1K ﹤0.01% 591
2025
Q2 		$13.7K Buy
+1,174
New +$16.4K ﹤0.01% 605

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Truvestments Capital's BNTC Position: Q1 2026 in Review

Truvestments Capital held its Benitec Biopharma (BNTC) position steady in Q1 2026 at 3,834 shares worth $40.8K. The position accounts for 0.01% of the portfolio, ranked #527.

Truvestments Capital first reported a position in BNTC in Q2 2025 and has held it in 4 quarters since. The position peaked at $51.6K in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Truvestments Capital held 3,834 shares of Benitec Biopharma worth $40.8K as of Q1 2026.
  • Truvestments Capital left its Benitec Biopharma share count unchanged in Q1 2026.
  • Benitec Biopharma made up 0.01% of Truvestments Capital's portfolio in Q1 2026, its #527 holding.
  • Truvestments Capital first reported a position in Benitec Biopharma in Q2 2025 and has held it in 4 quarters since.
  • Truvestments Capital's Benitec Biopharma position peaked at $51.6K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.